Otonomy - Corporate Presentation, March 22, 2022
Exciting times ahead for Otonomy with Phase 2 results and the highly anticipated results from the higher dosing cohort of 12 patients safety study.
Phase 3 in early 2023 with dosing to be decided based on the above results and subsequent meeting with the FDA.
The higher dose is 0.64 mg, which is double that of the original trial which was 0.32 mg.
The four case studies on the presentation are interesting. 63, 47, 37,46 points reduction in TFI.
That is quite impressive. I would certainly take that.